Institutional shares held 70.2 Million
88.3K calls
28.8K puts
Total value of holdings $2.8B
$3.52M calls
$1.15M puts
Market Cap $2.39B
62,263,500 Shares Out.
Institutional ownership 112.76%
# of Institutions 212


Latest Institutional Activity in XENE

Top Purchases

Q3 2024
Janus Henderson Group PLC Shares Held: 2.55M ($97.8M)
Q3 2024
Jpmorgan Chase & CO Shares Held: 977K ($37.4M)
Q3 2024
Siren, L.L.C. Shares Held: 744K ($28.5M)
Q3 2024
Samlyn Capital, LLC Shares Held: 1.02M ($39.1M)
Q3 2024
Vestal Point Capital, LP Shares Held: 825K ($31.6M)

Top Sells

Q3 2024
Invesco Ltd. Shares Held: 216K ($8.27M)
Q3 2024
Marshall Wace, LLP Shares Held: 1.2M ($45.8M)
Q3 2024
Balyasny Asset Management LLC Shares Held: 84.2K ($3.23M)
Q3 2024
Dimensional Fund Advisors LP Shares Held: 300K ($11.5M)
Q3 2024
First Light Asset Management, LLC Shares Held: 1.18M ($45.3M)

About XENE

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.


Insider Transactions at XENE

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
30.9K Shares
From 4 Insiders
Exercise of conversion of derivative security 30.9K shares
Sell / Disposition
55.5K Shares
From 8 Insiders
Open market or private sale 41.2K shares
Payment of exercise price or tax liability 5.93K shares
Other acquisition or disposition 8.4K shares

Track Institutional and Insider Activities on XENE

Follow Xenon Pharmaceuticals Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells XENE shares.

Notify only if

Insider Trading

Get notified when an Xenon Pharmaceuticals Inc. insider buys or sells XENE shares.

Notify only if

News

Receive news related to Xenon Pharmaceuticals Inc.

Track Activities on XENE